Today: 19 April 2026
MakeMyTrip to Buy Flamingo Transworld Stake as India Holiday Package Travel Grows
6 March 2026
1 min read

MakeMyTrip to Buy Flamingo Transworld Stake as India Holiday Package Travel Grows

Gurugram, March 6, 2026, 20:19 IST

MakeMyTrip on Thursday announced an agreement to take a majority stake in Flamingo Transworld, a regional tour operator, marking another move into bundled holiday packages that combine hotels, transport, and sightseeing. No price was disclosed, and closing conditions still apply.

This is a notable shift: hotels and packages now top the revenue charts for MakeMyTrip, and they’re expanding at a pace that’s leaving air ticketing behind. For the quarter ending Dec. 31, that division booked a 9.7% jump in revenue, reaching $161.4 million. Air ticketing, on the other hand, slid 2.1%. The company blamed it on tight domestic airline supply and a softer rupee.

Revenue for the quarter climbed 10.6% to $295.7 million. Gross bookings hit $2.78 billion, reflecting the total value of travel sold across the company’s platforms. That shift is part of the reason the company is chasing bigger exposure in package tours now, rather than holding out for a rebound in flight growth.

For nearly three decades, Flamingo has carved out its presence across Gujarat, Maharashtra, Rajasthan, and Madhya Pradesh. The company pushes its domestic and international group tours mostly via 51 offices—an offline setup that hands MakeMyTrip a stronger grip in regional markets.

Group CEO Rajesh Magow sees Flamingo as a strong match for MakeMyTrip’s packages growth push. Chief Operating Officer Mohit Kabra described it as “a profitable growth opportunity.” For Sanjay Shah, Flamingo’s co-founder, the partnership might be the key to creating a pan-India tour company.

This transaction adds to MakeMyTrip’s string of acquisitions, not a fresh direction. The company previously picked up Quest2Travel (corporate travel), Simplotel (hotel tech), BookMyForex (currency exchange), Savaari (intercity cars), and Happay (expense management), moves that have helped broaden its footprint in both leisure and business travel.

Competition is in the mix. Easy Trip Planners, a smaller competitor, has pushed to expand past just flights, while Yatra operates its own hotels-and-packages segment. Indian online travel players are all looking to carve out more of the country’s leisure spending.

Plenty remains unclear. The deal hasn’t closed yet, and MakeMyTrip is keeping mum on the price, only disclosing plans to take a majority stake. Meanwhile, marketing and sales promo spending jumped to $134.2 million in the first nine months of fiscal 2026, up from $123.2 million a year ago. Reported profit for the December quarter also slipped, coming in at $7.3 million—down sharply from $27.1 million.

Stock Market Today

  • RBC Capital Maintains Hold Rating on Charter Communications with $250 Price Target
    April 18, 2026, 9:23 PM EDT. RBC Capital analyst Jonathan Atkin reaffirmed a Hold rating on Charter Communications (CHTR) on April 13, setting a price target at $250. The stock closed at $226.30 the previous day. Atkin, known for a 65.43% success rate, focuses mainly on the real estate sector. Market consensus leans toward a Hold rating as well, with an average price target of $274.27. In its latest quarter ending December 31, Charter reported revenue of $13.6 billion and net profit of $1.33 billion, down from $13.93 billion and $1.47 billion year-over-year, signaling a slight earnings pullback.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Okta Stock Jumps After Q4 Beat, but Slowest Growth Forecast Since IPO Still Looms
Previous Story

Okta Stock Jumps After Q4 Beat, but Slowest Growth Forecast Since IPO Still Looms

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

Stock Market Today 07.03.2026

Go toTop